Back to School: How biopharma can reboot drug development. Access exclusive analysis here

NicVax: Phase IIb data

In the double-blind, placebo-controlled Phase IIb trial in 301 patients, 12-month abstinence was observed in 16%

Read the full 161 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE